MYCN expression in neuroblastoma: A mixed message?

Journal of Clinical Oncology

Volumn 18, Issue 21, 2000, Pages 3591-3594

  Matthay, K K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; CARCINOGENESIS; DIAGNOSTIC VALUE; GENE AMPLIFICATION; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 0034330372     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.21.3591     Document Type: Review

References (40)

1. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma
2. MYCN protein expression as a predictor of neuroblastoma prognosis
3. Immunohistochemical analysis of N-myc protein expression in neuroblastoma: Correlation with prognosis of patients
4. Expressions of N-myc and ras oncogene products in neuroblastoma and their correlations with prognosis
5. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas
6. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma
7. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas
8. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with non-amplified MYCN
9. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
10. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour
11. Molecular biology of neuroblastoma
12. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
13. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
14. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification
15. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis
16. Identification and characterization of the protein encoded by the human N-myc oncogene
17. Prendergast GC: Mechanisms of apoptosis by c-Myc
18. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
19. The N-myc oncogene in human neuroblastoma cells: Down-regulation of an angiogenesis inhibitor identified as activin A
20. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization
21. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma
22. Correlating telomerase activity levels with human neuroblastoma outcomes
23. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: A molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues
24. Telomerase expression in primary neuroblastomas
25. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis- retinoic acid: Children's Cancer Group
26. Loss of heterozygosity at lp36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study
27. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas
28. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture
29. N-myc can cooperate with ras to transform normal cells in culture
30. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line
31. The biological effects of antisense N-myc expression in human neuroblastoma
32. Characterization of human neuroblastoma cell lines that lack N-myc gene amplification
33. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification
34. Targeted expression of MYCN causes neuroblastoma in transgenic mice
35. Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma
36. N-myc oncogene RNA expression in neuroblastoma
37. Myc gene amplification and expression in primary human neuroblastoma
38. Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene
39. Successful treatment of stage III neuroblastoma based on prospective biologic staging: A Children's Cancer Group study
40. Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Group study